Kazuo Ito

Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

M. Hino, K. Kirito, K. Yamauchi, 2018, International Journal of Hematology.

A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis

K. Akashi, K. Takenaka, T. Tauchi, 2015, International Journal of Hematology.

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

K. Akashi, L. Shih, Jie Jin, 2013 .

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Jun Yu Li, K. Akashi, K. Takenaka, 2015, Leukemia & lymphoma.

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial

Y. Kanda, I. Matsumura, C. Nakaseko, 2018, International Journal of Hematology.